Sana Biotechnology, Inc. (SANA): Total Liabilities
$256.01M
As of 2025-12-31
$276.95M
As of 2026-06-30
-7.5%
3-year compound annual growth
-3.0%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $256.01M | +2.2% | 2026-03-03, Balance as of period end |
| 2024-12-31 | $250.52M | -9.8% | 2026-03-03, Balance as of period end |
| 2023-12-31 | $277.79M | -14.1% | 2025-03-17, Balance as of period end |
| 2022-12-31 | $323.40M | -19.3% | 2024-02-29, Balance as of period end |
| 2021-12-31 | $400.90M | +34.3% | 2023-03-16, Balance as of period end |
| 2020-12-31 | $298.58M | n/a | 2022-03-16, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Sana Biotechnology, Inc. (SANA) | 2025-12-31 | $256.01M | +2.2% |
| Allogene Therapeutics, Inc. (ALLO) | 2025-12-31 | $123.36M | -2.5% |
| Scholar Rock Holding Corp (SRRK) | 2025-12-31 | $158.78M | +49.4% |
| Maze Therapeutics, Inc. (MAZE) | 2025-12-31 | $42.16M | -3.4% |
| Cullinan Therapeutics, Inc. (CGEM) | 2025-12-31 | $39.64M | +25.9% |
| Monte Rosa Therapeutics, Inc. (GLUE) | 2025-12-31 | $215.60M | -0.1% |
| REGENXBIO Inc. (RGNX) | 2025-12-31 | $350.30M | +69.8% |
| Vor Biopharma Inc. (VOR) | 2025-12-31 | $628.44M | n/m |
| Scilex Holding Co (SCLX) | 2025-12-31 | $576.73M | +101.9% |
Compare SANA, ALLO, SRRK, MAZE side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗